Kelly, R J <br/><br/>
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Oct 2013 
 - 2601-2606 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdt249  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Apoptosis--drug effects<br/>Carboplatin--adverse effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Imidazoles--adverse effects<br/>Inhibitor of Apoptosis Proteins--antagonists & inhibitors<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Naphthoquinones--adverse effects<br/>Paclitaxel--adverse effects<br/>Survival<br/>Survivin<br/>Treatment Outcome